Pulmonary embolism in patients with COVID-19 and its treatment based on low-molecular-weight heparin

Hosseini, Amin; Bahramnezhad, Fatemeh

doi:10.1590/1516-3180.2020.0221.r2.22072020

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The decrease of D-dimer serum after we gave LMWH were happen in all of the patients with value 0.8 (range 0.4-1.8) vs. 0.4 (range 0.2-1.0) (Table 2 and Figure 1). Studies showed that heparin affect patients with COVID-19 positively, but noted that uncertainties remained about the heparin dose that would be most effective, and about monitoring of complications (Hosseini & Bahramnezhad, 2020).…”

Section: Resultsmentioning

confidence: 99%

The Use of Low Molecular Weight Heparin Among COVID-19 Patients in Udayana University Hospital, Bali

Harkitasari

Purnamasidhi

Rena

et al. 2022

RSD

View full text Add to dashboard Cite

Experts have speculated the potential of heparin administration as COVID-19 treatment modality, although scientific research regarding its effectivity, recommended dosage, and period are still minimal. This study aims to explore the capacity of LMWH as a medicament for COVID-19, in effort to provide scientific reference for further development of COVID-19 possible choice of treatment or medicament. A retrospective study was conducted in Udayana University Hospital, Bali, Indonesia. Data were sourced from laboratory-confirmed COVID-19 patients medical records during March 25 to July 31, 2020. Clinical, laboratory, treatment and use of LMWH data were reviewed and statistically processed. 42 patients we found Use of LMWH. The patient categorizes from moderate to severe COVID-19. 31 patients use of LMWH for prophylaxis and 11 patients use of LMWH for treatment. 7 patients were death in the hospital, and the other was survived. LMWH elevates coagulation dysfunction in COVID-19 patients. We believe that beneficial effects of LMWH as prophylaxis or treatment in COVID-19 patients.

show abstract

Section: Resultsmentioning

confidence: 99%

The Use of Low Molecular Weight Heparin Among COVID-19 Patients in Udayana University Hospital, Bali

Harkitasari

Purnamasidhi

Rena

et al. 2022

RSD

View full text Add to dashboard Cite

show abstract

SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm

Akhter

Hamali

Mobarki

et al. 2021

JCM

View full text Add to dashboard Cite

Pulmonary embolism (PE) is a life-threatening complication arising from venous thromboembolism with a difficult diagnosis and treatment and is often associated with increased mortality and morbidity. PE had a significantly low incidence prior to the COVID-19 epidemic. This condition saw a sharp surge during the COVID-19 pandemic, indicating an evident viral influence on PE’s pathophysiology in COVID-19 patients. The hypercoagulable state induced by the viral load seems to be the major contributor, and the classical causative factors seem to play a lesser role. PE in COVID-19 infection has become a mammoth challenge since the diagnosis is quite challenging due to overlapping symptoms, lack of prior-known predisposing risk factors, limited resources, and viral transmittance risk. Numerous factors arising out of the viral load or treatment lead to an increased risk for PE in COVID-19 patients, besides the fact that certain unknown risk factors may also contribute to the incidence of PE in COVID-19 patients. The management of PE in COVID-19 infection mainly comprises thromboprophylaxis and anticoagulant therapy with mechanical ventilation, depending on the risk stratification of the patient, with a post-COVID-19 management that prevents recurrent PE and complications. This review aims to discuss various aspects of COVID-19-infection-associated PE and major differential aspects from non-COVID-19 PE.

show abstract

Pulmonary embolism in patients with COVID-19 and its treatment based on low-molecular-weight heparin

Cited by 2 publications

References 14 publications

The Use of Low Molecular Weight Heparin Among COVID-19 Patients in Udayana University Hospital, Bali

The Use of Low Molecular Weight Heparin Among COVID-19 Patients in Udayana University Hospital, Bali

SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm

Contact Info

Product

Resources

About